Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
COVID-19: early-phase trial registry
68 of 299 indexed COVID-19 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #30 of 28,707 conditions by registered trial count.
299 US clinical trials · 68 currently recruiting · #30 of 28,707 conditions by registered trial count
COVID-19: 299 US clinical trials tracked, 68 recruiting.
COVID-19 is the subject of 299 registered US clinical trials on ClinicalTrials.gov, 68 of them currently open to new participants. 42 are in Phase 3-4 (later-stage) and 83 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 16 of these trials.
Enrollment posture brief
Registry condition covid-19
OPEN 68 | RECR 23% | LATE 42 | EARLY 83 | RANK #30 | SPON 16
Volume-matched condition peers
Nearest open-share peer: Hypogonadism (23% recruiting · 22 trials)
COVID-19 lists 68 open slots (23% of 299 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for COVID-19 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
COVID-19 is recruiting below its size-band peers.
68 of 299 indexed trials (22.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of COVID-19 trials is spread across many organizations.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 16 of 299 trials (5.4%). 173 distinct sponsors appear on at least one study for this condition label.
-
Typical COVID-19 enrolment sits around 245 participants.
Median target enrolment is 245 among the 299 trials that report a genuine target (sentinel values excluded). 96 of those (32.1%) plan for fewer than 100 participants.
-
COVID-19 splits between interventional and observational designs.
196 interventional and 103 observational studies make up this index (65.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
299 total, page 3 of 6
A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults
CyanVac
NCT05736835
COVID-19 Biorepository
University of Kansas Medical Center
NCT04568148
SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial
Milton S. Hershey Medical Center
NCT04802408
Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes
Massachusetts General Hospital
NCT02081326
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia
The University of Texas Medical Branch, Galveston
NCT05815485
Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection
Medical University of South Carolina
NCT04482673
Identification and Characterization of SARS-CoV-2 Specific CD8 T Cells in Humans
National Institute on Aging (NIA)
NCT04565067
Impact of Lp299v on Vascular Function in Patients With PASC
Medical College of Wisconsin
NCT05227170
Supplemental Citicoline Administration to Reduce Lung Injury Efficacy Trial (SCARLET)
Ohio State University
NCT05881135
COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation
Mayo Clinic
NCT04476953
A Clinical Observational Study of SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in Humans
National Institute on Aging (NIA)
NCT04852289
A First in Human Study to Evaluate the Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers
Rock BioMedical
NCT06878170
Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases
Northwestern University
NCT05822219
Safety, Reactogenicity, and Immunogenicity Trial of STX-S SARS-CoV-2 Vaccine in Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT07095231
High Resolution Micro OCT Imaging
University of Alabama at Birmingham
NCT03256773
A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults
Restorbio
NCT04584710
Famotidine vs Placebo for the Treatment of Non-Hospitalized Adults With COVID-19
Northwell Health
NCT04724720
COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE)
National Institutes of Health Clinical Center (CC)
NCT04595773
A Study of N-acetylcysteine in Patients With COVID-19 Infection
Memorial Sloan Kettering Cancer Center
NCT04374461
Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia
Ohio State University Comprehensive Cancer Center
NCT04466683
REsearching Covid-19 Outcomes in Diabetes (RECODE)
AdventHealth Translational Research Institute
NCT04805970
Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT07183709
Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
NCT03305341
Hyperpolarized 129Xe MRI of Survivors of COVID-19
University of Kansas Medical Center
NCT04659707
A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19
Pfizer
NCT06923137
Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
Pfizer
NCT05876377
Message From Local Pharmacy Team
University of Pennsylvania
NCT05613764
COVID-19 Citizen Science Expansion Project
University of California, San Francisco
NCT05548803
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
BioNTech SE
NCT04368728
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
Novavax
NCT04611802
Communities Fighting COVID-19!
San Diego State University
NCT05148936
Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
AstraZeneca
NCT04516746
Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral Infections
Evidation Health
NCT06207929
International Registry of Coronavirus (COVID-19) Exposure in Pregnancy
Pregistry
NCT04366986
Impact of Nudges on Downloads of COVID-19 Exposure Notification Smartphone Apps: A Randomized Trial
University of Pennsylvania
NCT05080179
The PAWS-COVID-19 (Pediatric AirWay complicationS COVID-19) Registry
Boston Children's Hospital
NCT04449042
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
ModernaTX
NCT05815498
A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls
Beth Israel Deaconess Medical Center
NCT04498442
Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic
Pregistry
NCT04385238
Test to Stay in School: COVID-19 Testing Following Exposure in School Communities
Duke University
NCT05052580
Use of Construal Level Theory to Inform Messaging to Increase Vaccination Against COVID-19
Brigham and Women's Hospital
NCT04871776
Michigan Medicine COVID-19 Cohort: Clinical Characteristics, Inflammatory Markers and Outcomes of Patients Hospitalized for COVID-19
University of Michigan
NCT04706533
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
Susanna Naggie, MD
NCT06042855
Epidemiology, Immunology and Clinical Characteristics of COVID-19 (EPIC3)
VA Office of Research and Development
NCT05764083
Respiratory Supports and COVID-19 Mortality
Yale University
NCT04832061
Can Vitamin D Reduce the Burden of COVID-19?
University of Chicago
NCT07128069
EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19
Pfizer
NCT04960202
Understanding Community Considerations, Opinions, Values, Impacts, and Decisions for COVID-19
University of California, Los Angeles
NCT04373135
Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19
Regeneron Pharmaceuticals
NCT04315298
Real World Study of COVID-19 in a Flyover Region
Tulane University
NCT04962347
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 28 |
| Phase 2 | 55 |
| Phase 3 | 31 |
| Phase 4 | 11 |
Top Sponsors
Named interventions
Most-linked intervention names on COVID-19 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on COVID-19 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this COVID-19 page
299 registered trials, 68 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 68 COVID-19 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most COVID-19 trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This COVID-19 condition card totals 299 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.